| ORIGINAL ARTICLE |
|
| Year : 2017 | Volume
: 10
| Issue : 3 | Page : 177-183 |
|
|
Experience of intravitreal triamcinolone acetonide for treatment of diabetic macular edema among Omani population
Ahmed Al Hinai1, Upender Krishen Wali1, Tayseer Abdul Rasool1, Syed G Rizvi2
1 Department of Ophthalmology, College of Medicine and Health Sciences, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman
2 Department of Family Medicine and Public Health, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman
Correspondence Address:
Ahmed Al Hinai
Department of Ophthalmology, College of Medicine and Health Sciences, Sultan Qaboos University Hospital, Muscat
Sultanate of Oman
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ojo.OJO_173_2016
|
|
|
PURPOSE: The purpose of this study was to evaluate the outcome of intravitreal (IVT) triamcinolone in diabetic macular edema (DME).
MATERIALS AND METHODS: A retrospective study of 42 eyes diagnosed clinically and supported with optical coherence tomography (OCT), with DME of more than 300 μm in thickness. All eyes were injected with a single IVT injection of preservative free triamcinolone acetonide (TA) with dose of 4 mg. Patients were subjected to visual acuity (VA) and OCT on each follow-up visit which was continued for 6 months. The total number of IVT injections given was 48. Six eyes had a repeat injection. None of the eyes had any other IVT injection within 6 weeks of TA. Twenty-one eyes were pseudophakic.
RESULTS: Mean age of the patients was 58.8 years. The mean central subfield thickness (CST) at baseline was 504.6 μm. At 6 weeks, the mean CST dropped by 183.6 μm (P < 0.00001). At 6-month follow-up, the mean CST had increased by 74.6 μm from 6 weeks level; however, the 6-month mean CST was 109 μ less than mean baseline thickness (P < 0.0005). The mean baseline VA was 0.80 LogMAR units. At 6 weeks, the mean VA dropped by 0.01 LogMAR. At 6 months, VA improved by 0.02 LogMAR units from baseline. Overall, VA improved in 47% eyes, dropped from baseline in 35% eyes, and remained unchanged in 18% eyes.
CONCLUSION: Triamcinolone acetonide is a safe, effective, and promising therapy in DME. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
